Published On: Wed, Oct 19th, 2016

Recently Changed Price Targets On MediWound Ltd. (MDWD)


A number of investment brokers have recently updated their price targets on shares of MediWound Ltd. (MDWD).

Most recent broker ratings

08/17/2016 – Wells Fargo began new coverage on MediWound Ltd. giving the company a “outperform” rating. They now have a USD 14 price target on the stock.

03/23/2016 – SunTrust began new coverage on MediWound Ltd. giving the company a “buy” rating. They now have a USD 13 price target on the stock.

02/03/2016 – MediWound Ltd. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 15 price target on the stock.

01/08/2016 – Brean Capital began new coverage on MediWound Ltd. giving the company a “buy” rating. They now have a USD 20 price target on the stock.

08/11/2015 – MediWound Ltd. had its “outperform” rating reiterated by analysts at Credit Suisse. They now have a USD 14 price target on the stock.

08/05/2015 – MediWound Ltd. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 13 price target on the stock.

04/23/2014 – Zacks began new coverage on MediWound Ltd. giving the company a “hold” rating.

04/14/2014 – BMO Capital Markets began new coverage on MediWound Ltd. giving the company a “outperform” rating. They now have a USD 20 price target on the stock.

The share price of MediWound Ltd. (MDWD) was down -1.45% during the last trading session, with a day high of 7.04. 16431 shares were traded on MediWound Ltd.’s last session.

The stock’s 50 day moving average is 7.52 and its 200 day moving average is 7.74. The stock’s market capitalization is 148.58M. MediWound Ltd. has a 52-week low of 5.66 and a 52-week high of 10.47.

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns. NexoBrid is based on the Company’s proteolytic enzyme technology. NexoBrid is a topically-applied product that removes eschar in approximately four hours without harming the surrounding healthy tissues. The Company offers NexoBrid in Europe and Israel. NexoBrid has been investigated in over 550 patients across approximately 15 countries and over four continents in approximately six completed Phase II and Phase III clinical studies.